Nektar Therapeutics Other Current Liabilities
Nektar Therapeutics (NKTR) had Other Current Liabilities of $1.46 million as of 2020-03-31, per its 10-Q filed 2020-05-08.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2020-05-08
- 2020-03-31: Other Liabilities, Current $1.46M.
- 2019-12-31: Other Liabilities, Current $1.69M; Other Liabilities, Current as first filed $924.00K.
- 2018-12-31: Other Liabilities, Current $493.00K.
- 2018-09-30: Other Liabilities, Current $6.61M.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2020-03-31 | $1.46M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $1.69M 10-Q · filed 2020-05-08 | $924.00K 10-K · filed 2020-02-28 |
| 2018-12-31 | $493.00K 10-K · filed 2020-02-28 | |
| 2018-09-30 | $6.61M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $10.09M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $105.00K 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $446.00K 10-K · filed 2019-03-01 | |
| 2017-09-30 | $3.92M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $5.94M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $2.39M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $7.41M 10-K · filed 2018-03-01 | $4.50M 10-K · filed 2017-03-01 |
| 2016-09-30 | $2.58M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $7.83M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $10.51M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $10.13M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $10.69M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $13.21M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $10.53M 10-Q · filed 2015-05-01 | |
| 2014-12-31 | $5.57M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $16.17M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $14.83M 10-Q · filed 2014-08-01 | |
| 2014-03-31 | $19.57M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $10.59M 10-K · filed 2015-02-26 | $14.12M 10-K · filed 2014-02-27 |
| 2013-09-30 | $12.80M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $16.30M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $12.67M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $9.41M 10-K · filed 2014-02-27 | $12.41M 10-K · filed 2013-03-01 |
| 2012-09-30 | $11.87M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $7.33M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $5.36M 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $4.68M 10-K · filed 2013-03-01 | $6.49M 10-K · filed 2012-02-29 |
| 2011-09-30 | $4.78M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $6.77M 10-Q · filed 2011-08-05 | |
| 2011-03-31 | $4.87M 10-Q · filed 2011-04-29 | |
| 2010-12-31 | $6.39M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |